EBGLYSS long-term data reported by Eli Lilly show durable skin clearance and relief from persistent itch for up to four years in patients with moderate-to-severe atopic dermatitis. These results materially strengthen the therapy's long-term efficacy profile and could support sustained commercial uptake and revenue durability for Lilly in this indication.
EBGLYSS long-term data reported by Eli Lilly show durable skin clearance and relief from persistent itch for up to four years in patients with moderate-to-severe atopic dermatitis. These results materially strengthen the therapy's long-term efficacy profile and could support sustained commercial uptake and revenue durability for Lilly in this indication.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
